ML 2-14

• CAT Number: I045319
• Molecular Formula: C40H38BrCl2N7O3S
• Molecular Weight: 847.65
• Purity: ≥95%
• Synonyms: N-[4-[4-[5-(4-bromophenyl)-2-(2-chloroacetyl)-3,4-dihydropyrazol-3-yl]phenoxy]butyl]-2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamide
• InChI: InChI=1S/C40H38BrCl2N7O3S/c1-23-24(2)54-40-37(23)38(28-8-14-30(43)15-9-28)45-33(39-47-46-25(3)49(39)40)21-35(51)44-18-4-5-19-53-31-16-10-27(11-17-31)34-20-32(48-50(34)36(52)22-42)26-6-12-29(41)13-7-26/h6-17,33-34H,4-5,18-22H2,1-3H3,(H,44,51)/t33-,34?/m0/s1
• InChIKey: KAGPSMVIFNDBGK-CDRRMRQFSA-N
• SMILES: CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NCCCCOC4=CC=C(C=C4)C5CC(=NN5C(=O)CCl)C6=CC=C(C=C6)Br)C7=CC=C(C=C7)Cl)C

ML 2-14 (Cat No.: I045319)is a synthetic small-molecule inhibitor designed to selectively target and modulate specific signaling pathways involved in cancer progression, particularly those related to tyrosine kinases. It has shown promising activity in preclinical studies by inhibiting tumor cell proliferation, inducing apoptosis, and suppressing metastasis in various cancer models. ML 2-14’s mechanism involves blocking aberrant kinase signaling, making it a potential candidate for targeted cancer therapy. Its selectivity and potency offer opportunities for further development in personalized oncology treatments.

Reference

[1]. Luo M, et al. Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function. Cell Chem Biol. 2021;28(4):559-566.e15.
[Content Brief]